Antipsychotic Polypharmacy: Is There Evidence for its Use?

  title={Antipsychotic Polypharmacy: Is There Evidence for its Use?},
  author={Vijayalakshmy Patrick and Elizabeth Levin and Steven J. Schleifer},
  journal={Journal of Psychiatric Practice},
Antipsychotic polypharmacy occurs frequently in clinical practice; however, there is a lack of controlled clinical studies testing the efficacy of the combinations used. The purpose of this literature review was to examine studies and other reports that have assessed the incremental benefits and deficits of combination antipsychotic therapy versus monotherapy. A PUBMED search covering a 26-year period from 1976 to 2002 was conducted. The search was limited to clinical trials, case series, and… 

Polypharmacy With Second-Generation Antipsychotics: A Review of Evidence

Polypharmacy with SGAs is not uncommon, with prevalence varying widely depending on setting and patient population, despite limited support from blinded, randomized, controlled trials or case reports that employed an A-B-A (monotherapy-combination therapy-monotherapy) design and adequate dosing and duration of treatment.

Preclinical and Clinical Investigation of Antipsychotic Polypharmacy: What Is the Evidence?

The specific effects of antipsychotic co-treatment in different symptoms dimensions, its interactions, adverse reactions and associations with medical morbidity and mortality remain to be further examined through rigorously designed clinical trials and prospective epidemiological studies.

A Study of Polypharmacy with Second Generation Antipsychotics in Patients with Severe and Persistent Mental Illness

Polypharmacy with SGAs is quite frequent among chronic inpatients with severe and persistent mental illness despite a limited empirical database supporting its use, and the results of this pilot study do not demonstrate the effectiveness and safety of this practice.

Augmenting Clozapine Response in Treatment-Resistant Schizophrenia

The present chapter focuses on controlled evidence available to guide clinical decision making in the face of clozapine partial response, and underscores the need for substantially more work along these lines.

Aripiprazole in Treatment-refractory Schizophrenia

The case of a 58-year-old female patient with treatment-refractory schizophrenia who was successfully switched from clozapine 300 mg/day to aripiprazole 20  mg/day because of changes in consciousness is described.

Antipsychotic Polypharmacy among Psychiatric Patients in Hospital Kajang, Malaysia

It was found from this study that duration of illness had statistically significant association with antipsychotic polypharmacy (P<0.05), and prescription of antipsychotics for diabetics and obese patients was concerned with severe side effects.

Combination antipsychotic therapy in psychiatric outpatient clinics in Taiwan.

Remission of Positive and Negative Symptoms in Refractory Schizophrenia with a Combination of Haloperidol and Quetiapine: Two Case Studies

The mechanism of action resulting in treatment success in the cases described here may be related to the fact that the two medications have different receptor affinities and patterns of receptor coverage, which provides robust coverage in areas generating positive symptoms, while the second generation antipsychotic quetiapine also has effects on areas that generate negative symptoms.



Polypharmacy among psychiatric patients

  • E. Hemminki
  • Psychology, Medicine
    Acta psychiatrica Scandinavica
  • 1977
There seems to be no evidence from clinical trials defending the frequent polypharmacy among psychiatric patients in Helsinki, and a radical reduction in the number of psychotropic drugs prescribed for psychiatric patients is apparently desirable.

When symptoms persist: clozapine augmentation strategies.

A synthesis of the available literature on the range and efficacy of clozapine augmentation strategies that may be used when monotherapy fails shows that current systematic efforts to enhance the treatment of patients with adjunctive therapies are worthy of being studied in carefully conducted clinical trials.

Combined use of Risperidone and Olanzapine in the Treatment of Patients with Resistant Schizophrenia: A Preliminary Case Series Report

The results suggest that this combination of risperidone-olanzapine combination may be useful, but the efficacy of this drug combination should be confirmed in larger study populations before its clinical application is considered.

Risperidone augmentation of clozapine.

Risperidone may be reasonably construed to be a medication with efficacy somewhere between clozapine and classical neuroleptics, and it may be especially well suited for use with clozAPine as a part of an augmentation strategy.

Risperidone as an adjunct to clozapine therapy in chronic schizophrenics.

In an open 4-week trial involving 12 treatment-resistant schizophrenic patients, the addition of risperidone to clozapine was well tolerated and produced significant reduction of symptoms, suggesting that this may be a useful clinical approach.

Antipsychotic Polypharmacy: A Survey of Discharge Prescriptions from a Tertiary Care Psychiatric Institution

Although antipsychotic polypharmacy persists today, as it has over the past 30 years, evidence-based data to support this controversial treatment strategy is lacking and clinicians are relying on their clinical experience, and perhaps intuition, to design antipsychotics polyphARMacy treatment protocols.

Effect of Clozapine-Quetiapine Combination Therapy on Weight and Glycaemic Control

An unexpected, yet welcome, clinical effect of quetiapine is its apparent propensity to induce weight loss and improve glycaemic control in patients who gain weight and develop diabetes on clozapine therapy.